|
|
MOLYBDENUM REDUCES THE EFFICACY OF THE DRUG
|
THYROID, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
THYROXINE EFFICACY IS REDUCED ON CO-ADMINISTRATION
|
THYROID ADMINISTRATION TO A DIGITALIZED, HYPOTHYROID PATIENTS MAY INCREASE THE DOSE REQUIREMENT OF DIGOXIN
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|